REG - Craven House Capital - Interim Results
27/02/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250227:nRSa5988Ya&default-theme=true
RNS Number : 5988Y Craven House Capital PLC 27 February 2025
27 February 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Craven House Capital PLC
("Craven House" or the "Company")
Unaudited Interim Report for the period ended 30 November 2024
CRAVEN HOUSE CAPITAL PLC
INVESTMENT MANAGER'S REPORT FOR THE SIX MONTH PERIOD ENDED
30 NOVEMBER 2024
Statement by the Investment Manager
The Company's investment portfolio comprises shareholdings in two quoted
early-stage pharmaceutical companies listed in Stockholm and ongoing minority
shareholdings in five private Swedish-managed businesses operating in the
eCommerce and pharmaceutical sectors. These private investee companies remain
at a 'pre-revenue' stage of business development and their respective
valuations have been maintained at zero. The valuations of Craven's portfolio
at the end of the period are as follows:
Investment Value at 30 Nov 2024 Value at 31 May 2024
Shares in Bio Vitos Pharma AB $235,003 -
Shares in Quia Pharma AB $361,138 -
Shares in Bio Vitos Medical Limited - $515,000
As previously disclosed, RoseMonkey Ltd (in which Craven is a 24.4%
shareholder) was awarded 1,416,007,811 shares in QuiaPeg Pharma AB in the
prior period. During the current period, RoseMonkey distributed a
proportionate amount of those shares to Craven House. Craven House therefore
received 345,505,096 shares representing 23.2% of QuiaPeg. There was no other
material activity during the current period.
Desmond Holdings Ltd
Investment Manager to Craven House Capital Plc
CRAVEN HOUSE CAPITAL PLC
STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
Six months ended Year Ended
30 Nov 2024 30 Nov 2023 31 May 2024
Note (Unaudited) (Unaudited) (Audited)
$'000 $'000 $'000
CONTINUING OPERATIONS
Changes in fair value 109 - (621)
Administrative expenses (72) (77) (197)
OPERATING PROFIT/(LOSS) 37 (77) (818)
Interest expense (39) (37) (75)
LOSS BEFORE INCOME TAX (2) (114) (893)
Income tax 2 - - -
LOSS FOR THE PERIOD (2) (114) (893)
Earnings per share expressed
In cents per share:
Basic and diluted 5 (0.05) (2.95) (23.11)
CRAVEN HOUSE CAPITAL PLC
STATEMENT OF FINANCIAL POSITION
AS AT 30 NOVEMBER 2024
Six months ended Year Ended
30 Nov 2024 30 Nov 2023 31 May 2024
(Unaudited) (Unaudited) (Audited)
Note $'000 $'000 $'000
ASSETS
NON-CURRENT ASSETS
Investments at fair value through
profit or loss 3 596 1,136 515
596 1,136 515
CURRENT ASSETS
Trade and other receivables 24 25 29
Cash and cash equivalents 28 - 2
52 25 31
TOTAL ASSETS 648 1,161 546
EQUITY
SHAREHOLDERS' EQUITY
Called up share capital 4 3,802 3,802 3,802
Share premium 11,153 11,153 11,153
Accumulated deficit (16,234) (15,453) (16,232)
TOTAL EQUITY (1,279) (498) (1,277)
LIABILITIES
CURRENT LIABILITIES
Trade and other payables 305 114 241
NON-CURRENT LIABILITIES
Other payables 1,622 1,545 1,582
TOTAL LIABILITIES 1,927 1,659 1,823
TOTAL EQUITY AND LIABILITIES 648 1,161 546
CRAVEN HOUSE CAPITAL PLC
STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
Called up share capital
$'000 Share premium Accumulated deficit
$'000 $'000 Total
$'000
Balance at 1 June
2023 3,802 11,153 (15,339) (384)
Loss for the period - - (114) (114)
Balance at 30 November 2023
3,802 11,153 (15,453) (498)
Loss for the period - - (779) (779)
Balance at 31 May
2024 3,802 11,153 (16,232) (1,277)
Loss for the period - - (2) (2)
Balance at 30 November
2024 3,802 11,153 (16,234) (1,279)
CRAVEN HOUSE CAPITAL PLC
STATEMENT OF CASH FLOWS
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
Six months ended Year Ended
30 Nov 2024 30 Nov 2023 31 May 2024
(Unaudited) (Unaudited) (Audited)
$'000 $'000 $'000
Cash flows from operating activities
Loss before income tax (2) (114) (893)
Adjustments for non-cash items
Fair value adjustment arising on investments (109) - 621
Decrease in trade and other receivables 5 13 9
Increase in trade and other payables 65 5 132
Interest expense 39 37 75
Net cash used in operating activities (2) (59) (56)
Cash flows from investing activities
Disposal of investments 28 - -
Net cash flows from investing activities 28 - -
Cash flows from financing activities
Loans received - 55 54
Net cash flows from financing activities - 55 54
Net increase/(decrease) in cash and cash equivalents
26 (4) (2)
Cash and cash equivalents at the beginning
of the period 2 4 4
Cash and cash equivalents at the end of the period
28 - 2
CRAVEN HOUSE CAPITAL PLC
NOTES TO THE FINANCIAL INFORMATION
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
1. ACCOUNTING POLICIES
General Information
Craven House Capital Plc is a company incorporated in the United Kingdom under
the Companies Act 2006. The address of the registered office is given on the
company information page. The Company is listed on the AIM Market of the
London Stock Exchange (ticker: CRV).
The next annual financial statements of Craven House Capital Plc will be
prepared in accordance with International Financial Reporting Standards and
IFRIC interpretations and with those parts of the Companies Act 2006
applicable to companies reporting under UK adopted international standards.
Accordingly, the interim financial information in this report has been
prepared using accounting policies consistent with IFRS. IFRS are subject to
amendment and interpretation by the International Accounting Standards Board
(IASB) and the International Financial Reporting Interpretations Committee
(IFRIC) and there is an on-going process of review and endorsement by the
European Commission. The financial information has been prepared on the basis
of the IFRS that the directors expect to be applicable as at 31 May 2025.
The financial information has been prepared under the historical cost
convention, except to the extent varied for fair value adjustments required by
accounting standards, and in accordance with International Financial Reporting
Standards and IFRIC interpretations and with those parts of the Companies Act
2006 applicable to companies reporting under UK adopted international
standards. The principal accounting policies have been applied to all periods
presented.
This financial information is unaudited and does not constitute statutory
financial statements within the meaning of Section 434 of the Companies Act
2006. The financial statements of the Company for the year ended 31 May 2024,
which were prepared in accordance with International Financial Reporting
Standards and IFRIC interpretations and with those parts of the Companies Act
2006 applicable to companies reporting under UK adopted international
standards, have been reported on by the Company's auditors and delivered to
the Registrar of Companies. The report of the auditors was unqualified and did
not include any statement under Section 498 of the Companies Act 2006.
This financial information is presented in United States dollar, rounded to
the nearest $'000.
The directors do not propose the issuance of a dividend.
The interim financial information for the six months ended 30 November 2024
was approved by the directors on 26 February 2025.
Going concern
The directors consider that the Company is well placed to manage its business
risks successfully and have a reasonable expectation that the Company has
adequate resources to continue in operational existence for the foreseeable
future. Thus, they continue to adopt the going concern basis of accounting in
preparing the financial information.
CRAVEN HOUSE CAPITAL PLC
NOTES TO THE FINANCIAL INFORMATION - continued
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
2. Taxation
No tax charges arose in the period or in comparative periods as a result of
losses incurred.
3. Investments at fair value through profit or loss
Equity investments
$'000
Total
$'000
As at 1 June 2024 515 515
Disposals (28) (28)
Fair value movement 109 109
As at 30 November2024 596 596
The value of Investments represents the Company's holdings in two quoted,
early-stage pharmaceutical companies, listed in Stockholm. Both of these
holdings are valued on a mark-to-market basis as follows:
341,405,096 shares in Quia Pharma AB, which had a share price of EUR 0.001 as
at 30 November 2024 resulting in a total valuation of USD $361,138.
4,052,046 shares in Bio Vitos Pharma AB, which had a share price of SEK 0.632
as at 30 November 2024 resulting in a total valuation of USD $235,003.
The company retains its holdings in the below-named five privately owned UK
entities which are all unquoted and have therefore been measured on a Level 3
basis as no observable market data is available. Further information on each
investment holding is as follows;
Shares in Garimon Limited are valued at $nil representing a 29.9% holding.
Garimon Limited is the owner of "Magazinos.com", an on-line media magazine and
periodical content provision service. Despite the potential future value of
this investment, the fair value has been impaired to zero due to the current
absence of tangible arm's length or market-based valuation metrics.
Shares in Stormfjord Limited are valued at $nil representing a 25.5% holding.
Stormfjord is the owner of the domain www.onebas.com (http://www.onebas.com) ,
an optimised search engine providing a portal to music content freely
circulating online. Despite the potential future value of this investment, the
fair value has been impaired to zero due to the current absence of tangible
arm's length or market-based valuation metrics.
CRAVEN HOUSE CAPITAL PLC
NOTES TO THE FINANCIAL INFORMATION - continued
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
3. Investments at fair value through profit or loss (continued)
Shares in Honeydog Limited are valued at $nil representing a 29.9% holding.
Honeydog Limited is the 25% owner of the entity which owns the licence to
manufacture and distribute the chemotherapy drug, Temodex, which is used in
the treatment of brain tumours. Despite the potential future value of this
investment, the fair value has been impaired to zero due to the current
absence of tangible arm's length or market-based valuation metrics.
Shares in Rosedog Limited are valued at $nil representing a 28.6% holding,
unchanged from the prior year. Rosedog Limited is the owner of TV Zinos
(www.tvzinos.com), a website which offers a number of free-to-view television
channels. Despite the potential future value of this investment, the fair
value has been impaired to zero due to the current absence of tangible arm's
length or market-based valuation metrics.
Shares in Bio Vitos Medical Limited are valued at $nil representing a 24.5%
holding. Bio Vitos is the owner of the licence to market a patented heart drug
'Succifer' (also marketed as 'Inofer'). The drug has been demonstrated to
improve iron uptake in patients with chronic heart conditions.
The businesses of all of the above portfolio investments are presently
loss-making although their cost bases are low and there is minimal committed
future expenditure, meaning that the extent and timing of the Company's
further investment in the businesses are highly controllable. The Company and
the incumbent management teams of the investee companies will continue to work
together with the aim that these businesses become financially self-sustaining
and generating surpluses within the short- to medium-term and to crystallise
additional capital value for shareholders through strategic, third-party
partnerships.
4. Called up share capital
Authorised, issued and fully paid share capital as at 30 November 2024 is as
follows:
Number Class: Nominal 30 Nov 31 May
Value 2024 2024
(Unaudited) (Audited)
$'000 $'000
3,863,590 Ordinary $1.00 3,802 3,802
3,802 3,802
The aggregate nominal values of the ordinary shares include exchange
differences arising from the translation of shares at historic rates and the
translation at the rate prevailing at the date of the change in functional
currency.
The aggregate nominal values of the ordinary shares include exchange
differences arising from the translation of shares at historic rates and the
translation at the rate prevailing at the date of the change in functional
currency.
CRAVEN HOUSE CAPITAL PLC
NOTES TO THE FINANCIAL INFORMATION - continued
FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024
5. Earnings per share
The calculation of basic earnings per share is based on the loss attributable
to the equity holders of $2,000 divided by the weighted average number of
shares in issue during the period of 3,863,590 (six months ended 30 November
2023: loss of $114,000 and 3,863,590 shares; year ended 31 May 2024: loss of
$893,000 and 3,863,590 shares).
6. Related party disclosures
Craven Industrial Holdings Plc
At the period end, the outstanding balance due to Craven Industrial Holdings
Plc was $1,622,000. Despite the common director in Mr M J Pajak, the board of
Craven House Capital Plc do not believe that Craven House Capital Plc
or Craven Industrial Holdings Plc are able to exert control or influence
over each other and neither are accustomed to act in accordance with
instructions from the other.
7. Events after the reporting period
None.
For further information please contact:
Craven House Capital Plc Tel: 0203 286 8130
Mark Pajak
www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)
SI Capital Tel: 01483 413500
Broker
Nick Emerson
www.sicapital.co.uk (http://www.sicapital.co.uk/)
SPARK Advisory Partners Limited Tel: 0203 368 3550
Nominated Adviser
Matt Davis
www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)
About Craven House Capital:
The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR DQLFLELLFBBQRecent news on Craven House Capital
See all newsREG - Craven House Capital - Interim Results
AnnouncementREG - Craven House Capital - TR-1: Notification of major holdings
AnnouncementREG - Craven House Capital - Result of AGM
AnnouncementREG - Craven House Capital - Annual Results For Year Ended 31 May 2024
AnnouncementREG - Craven House Capital - Investee company update: RoseMonkey Ltd
Announcement